Efficacy of rituximab in refractory neuromyelitis optica.
Fiche publication
Date publication
juin 2016
Journal
Multiple sclerosis (Houndmills, Basingstoke, England)
Auteurs
Membres identifiés du Cancéropôle Est :
Pr DE SEZE Jérôme
Tous les auteurs :
Collongues N, Brassat D, Maillart E, Labauge P, Ouallet JC, Carra-Dalliere C, Moreau T, Bourre B, Papeix C, Brochet B, Audoin B, Vukusic S, de Seze J, Marignier R,
Lien Pubmed
Résumé
Despite a growing use of rituximab (RTX) in neuromyelitis optica (NMO), data are lacking in patients with refractory NMO (RNMO), defined as cases with at least one relapse during immunosuppressive therapy.
Mots clés
Adolescent, Adult, Aged, Body Mass Index, Disability Evaluation, Disease Progression, Female, Humans, Immunosuppressive Agents, adverse effects, Male, Middle Aged, Neuromyelitis Optica, diagnosis, Recurrence, Remission Induction, Risk Factors, Rituximab, adverse effects, Time Factors, Treatment Outcome, Young Adult
Référence
Mult. Scler.. 2016 06;22(7):955-9